Yesterday, 2026 July 15, the 15 July, the 2026 July, the 2026 July, the 2026 July. VRTA11 (Factor Truth FII) credit credit R$0.85 for quote referring to June. It is the 16X consecutive month with exactly that value - a sequence that, for many quotes, became synonymous with tranquility. A dividend that does not change becomes that kind of line that no one questions.
Only the number that really matters wasn't on the income notice. It was in the managerial report: the April box result of 2026 generated 2026 generated. R$1.12 for quote — 32% above the R$0.85 distributed. The difference has not disappeared. She went to the reservation, which rose from R$0.47 to R$0.47. R$0.76 for quote. In other words: the fund is earning more than it pays, and keeping the surplus.
Here lies the tension of this article. If the bottom has improved from the inside, why did the unit fall to the bottom? R$74.10XR, a P/VP of P/VP 0,877 — the deepest discount of the last 12 months? The answer lies in three names that frighten the market: Gafisa/Vorcaro, Fragnani II and the growing high yield credit strategy. Let's get to the facts, no cheerleading.
The two questions that dominate the Club FII about the VRTA11X Club FII
"Does the Gafisa/Vorcaro case affect my dividend?" — Today, not. The two CRIs of Gafisa in the portfolio are up to date and add about 7% of PL, with real guarantees (fiduciary alienation of real estate, assignment of receivables, guarantee of natural person and reserve fund). What changed was not the default – it was the legal complexity around the company. The risk is reputational and feasibility risk, not immediate default.
"Is Fragnani going to bring down the dividend?" — It won't. The CRI Fragnani II (R$69.2M) was already there. 100% Provisioned Provisioned: accounting, the fund has already marked that asset to zero. The DPS does not fall because of this because the cash comes from the other 67 CRIs who pay normally — the very R$1.12 generated in April confirms. The blow has already been given in the VP/unit (about R$4.44), not in the monthly income.
What generated R$1.12 — and why it changes reading
It is worth separating two concepts that many people confuse. O O O profit or loss on operating income is how much money actually went into the fund in a month — interest and monetary correction of the received CRIs. It’s already the DPS That's how much the fund manager decides to distribute. When the result exceeds the DPS, the difference is retained as reserve. When it is the opposite, the fund pulls from the reserve to maintain the payment.
In April of 2026, VRTA11 generated R$1.12 and distributed R$0.85 — a coverage of 132%. That's not punctual luck. The portfolio of the company 68 CRIsXX Pay a fee average of IPCA+8.1%% over the equity unit, com com 91% indexed to IPCA++ and only 9% to CDI+. With current inflation still pushing the price index, the monetary correction of these papers enriches the receipts.
The reserve grows from R$0.47 to R$0.76 per unit imports for a practical reason: it is margin of security. If a month comes weak (a CRI delays, inflation retreats), the fund manages to keep the R$0.85 without fears. In paper funds, this retained "fat" is what separates the sustainable dividend from the dividend that is made up with old box. In VRTA11, fat is increasing—a healthy sign.
Leverage: growth driver or risk lurking?
The background carries loads. R$84.7 million in operations committed to CDI+0.74%. Translating: the fund manager borrows cheap money (near cost of CDI) and uses this feature to buy CRIs that yield much more. It is the classic classic. Carry Trade — gain on the spread between what is paid to collect and what is received when applying.
The account is attractive today. Capture the CDI+0.74% and allocate in roles like the new CRIsX%. THCM 2 (R$24M, IPCA+12%) and and y Guestier 2 series (R$3.5M, IPCA+12%) It generates a wide brute spread spread. While expensive money returns IPCA+12% and the money taken costs close to the CDI, the quoter gains leveraged.
The risk appears on the other side of the cycle. The cost of leverage is tied to CDI, but a relevant portion of the portfolio is tied to IPCA. If the Selic falls (the projection is something close to 11% in 12 months) and inflation slows down together, the spread compresses at both ends: the cost falls slowly while the revenue indexed to IPCA may shrink faster. Leverage amplifies gain when the tide is in favor and amplifies loss when it turns. For now, it is wind in favor — but it is a variable that the unit holder needs to follow month by month.
Gafisa/Vorcaro — what really changes for the quoter
The noise began with Operation Compliance Zero, of the Federal Police, which investigates Gafisa for alleged shielding of assets via the Bergamo fund (Trustee DTVM), with the participation of Daniel Lopes Monteiro and a "parallel compliance" scheme linked to Daniel Vorcaro. The name Gafisa light alert in any credit wallet is natural.
In the VRTA11, the display is two CRIs: the Epitatius (CDI+4.0%, rating BBB-) and is the Oscar Freire (IPCA+10%, rating BBB), which together represent about 7% of PL. Both are Both are In the daytime. and are structured with real guarantees — fiduciary sale of real estate, transfer of receivables, guarantee of natural person and reserve fund. A day-to-day operation with collateral is not the same as a clean loan to the company's parent company.
What actually changes: if the judicial situation of Gafisa deteriorates, the judicial situation of Gafisa will deteriorate. Feasibility Execution The guarantees become more complex. Executing a fiduciary alienation is simple when there is no societal dispute; it turns into a novel when there is an ongoing investigation of patrimonial shielding. It’s not “it’s going to break tomorrow” — it’s “it’s gotten harder and more time-consuming to turn the guarantee into money if you need it.” For a quotationist, this means that these 7% of the PL deserve redoubled surveillance in the next reports.
Fragnani II — meaning "100% provisioned"
Provisioning (PDD, provision for doubtful debtors) is the accounting act of recognizing that a credit will probably not be paid and reducing its value in the books of the fund. The CRIX The CRI €2500 (€750) Fragnani ZQXX0ZQXXM It is in judicial recovery and was marked a. the the zero zero zero the: the VRTA11 has already assumed the loss accounting. It was this event that knocked down the VP/unit in about R$4.44XR.
The counterintuitive good news: as the loss has already been acknowledged, it no longer weighs on the monthly dividend — the cash comes from the other healthy 67 CRIs. And there is asymmetry in favor: if the judicial recovery returns some value (partial recovery), that money enters as it does. Up Up Up Up Up, because the asset today is worth zero in books. If the recovery is zero, the money has simply disappeared — but the price is already in the bucket.
Unimed-DF — the next point of the risk map.
Search for: 2.63% PLX% 2.63% is in a CRI of Unimed-DF, paid to IPCA+8.8%. The point of attention is not the operation itself — which is up to date — but the sector. Supplemental health has accumulated bad history: in 2025, cases such as Unimed-Taubaté and Unimed Norte/Norteeste entered into judicial recovery, exposing the fragility of medical cooperatives in the face of high sinistrality and actuarial imbalance.
The Unimed-DF has no documented problem yet, and the IPCA+8.8% is a risk premium matching the BBB category. But it's a name that requires active monitoring — the kind of exposure that can go from "quiet" to "worrying" in a few quarters if the industry cracks again. It is not a reason to sell; it is a reason to read the management report carefully.
The portfolio in numbers.
| Indica Indica Indica/ Indica Indica Indica/ Indica Indica Indica Indica | valor valor valor |
|---|---|
| Active As As As As | 68 CRIs + 9 Paper FIIs = 77 positions |
| Composition of PLX | CRIs 89.3% | FIIs paper 9.6% | Box 2.6% | Compromissed -1.6% |
| B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B b B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B b B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B | IPCA+8.1% (over unit) |
| Duration Duration | 4.58 years years |
| Indexação (index) | 91% IPCA+ | 9% CDI+ |
| Quality of credit Quality of credit | 87.9% between AAA and A- (proprietary rating FAR) |
| Inadimplência | 0,1% |
| Cotistas Cotistas | 104.232 |
| VP/cotation | R$84.44 (Mar/2026) |
The top ten positions show a pulverized portfolio — no asset passes from 3.92% to PL% — but with sectorial concentration in embedding and infrastructure:
| Devedor Devedor | % ZQX0ZQQXX % | the Tax Tax Tax Tax | Rating |
|---|---|---|---|
| Gafisa S.A. (Epitaph) ⚠️ ⚠️ | 3,92% | CDI+4.0%% | BBB- |
| Summus Engineering Summus Engineering | 3,70% | IPCA+11.5%% | BBB+ |
| Directional Engineering Directional Engineering | 3,37% | IPCA+4.8%% | AA |
| Solar Power Plants Cajuru/Montes Claros | 3,11% | IPCA+10.0%% | BBB+ |
| Gafisa S.A. (Oscar Freire) ⚠️ | 3,10% | IPCA+10.0%% | BBB |
| BB Technology (BTS Space Y)) | 3,05% | IPCA+6.7%% | AAA |
| Arteris S.A. | 2,99% | IPCA+5.1%% | AA- |
| LAR Cooperativa Agroindustrial Cooperativa Agroindustrial | 2,81% | IPCA+8.7%% | The The The The The The The The |
| Canopus/Status of SP (PPP III) | 2,76% | IPCA+6.0%% | AA |
| Unimed-DF ⚠️ | 2,63% | IPCA+8.8%% | BBB |
The management is of the management. Factor Resource Management Factor (FAR), touching the bottom for 15 years, with rate of 15 years. 1.0% per annum and no performance rate.. It is a competent regional fund manager, but with less over-the-counter musculature and less ability to absorb errors than giants like Kinea or Mauá. In a wallet that moves towards rising high yields, this difference in margin of error weighs.
Verdict editorial editorial
Note 7.1/10 — ACUMULAR.
To whom: Free monthly income search of IR with inflation protection (91% IPCA+), accepts unit oscillation and wants to diversify the credit installment outside the pure core high grade.
It's not for whom: expects DPS growing month by month, does not tolerate idiosyncratic credit risk (Gafisa, Fragnani, Unimed-DF) or wants exclusively AAA roles of giant fund manager.
The entry point: The entry point: The P/VP of 0.877 is the deepest discount of the last 12 months. For those who already understand and accept the risks, it is a window — not a price "for free".
Against the pairs: VGIR11 (7.4, better liquidity) > VRTA11 (7.1) > 7.1 PORD11 (6.9) > > AFHF11 (6,5).
Conclusion Conclusion.
The data that changes the narrative is not the R$0.85 repeated by 16 at the time — it is the R$1.12 generated against R$0.85 distributed. The fund is earning more than it pays, the reserve has risen from R$0.47 to R$0.76 per share, and the dividend has loose hedge. In this regard, the VRTA11 is stronger than the price suggests.
But the risks are real and nameable: the judicial unfolding of Gafisa/Vorcaro risk over 7% of PL, the Fragnani II to zero (with upside only if there is recovery), the leverage of R$84.7 millions that bets on the maintenance of the spread. A regional fund manager has less room for error to touch this strategy than market leaders.
The synthesis is direct. Who already has VRTA11 and bought understanding the thesis of diversified credit: keep and reinvest — the dividend coverage is intact. The P/VP of 0.877 is the most attractive point of the last 12 months, provided that the purchase comes accompanied by full science that Gafisa, Fragnani and the leverage are parts of the package, not footnotes. Complete and up-to-date analysis of the fund at Our VRTA11 page.
